Skip to main content
Caplight Logo









Breakthru Medicine

Breakthru Medicine

Private
Phoenix, ArizonaHealthcare & Life Scienceshttps://www.breakthrumed.com/

Last Round

Series A

Jan 29, 2026

Total Funding Raised

$60M

Company Overview

Breakthru Medicine is a biotechnology company developing oncology therapies for solid cancers using antibody-drug conjugates, small molecules, and molecular glues.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Non-AI

Keywords

oncology therapeuticsdrug discoveryprecision oncologysmall molecule therapeuticsantibody-drug conjugateADCmolecular glueprotein degradationtargeted therapybiotech startupdrug pipelinehard-to-drug targetspreclinical developmentbiopharmatherapeutic assets

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Breakthru Medicine Comparables

Compare Breakthru Medicine with similar companies based on industry and business-model similarity.

Breakthru Medicine comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Fortitude Biomedicines
87%
Nested Therapeutics
85%
Kivu Biosciences
83%

Breakthru Medicine Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJan 29, 2026

Key People

Founding team and executive leadership

Steve Potts

CEO and Co-Founder

Founding Team

Breakthru Medicine Investors

Notable investors and investment history

Breakthru Medicine investors
InvestorRounds
Eshelman VenturesSeries A, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 22, 2026

    Monthly visitors grew 305% MoM, reaching 2.4K.

  • Jan 29, 2026

    Company emerges from stealth with Series A financing.

Breakthru Medicine Filings

Explore SEC and related filing metadata, where available.

Breakthru Medicine filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Breakthru Medicine's valuation, stock price, and market status.

Is Breakthru Medicine a public or private company?

Breakthru Medicine is a private company.

What is the current stock price of Breakthru Medicine?

Breakthru Medicine is a private company with no public stock price. No recent secondary market data is available.

How much is Breakthru Medicine worth (valuation)?

Valuation information for Breakthru Medicine is not publicly available.

Can I buy Breakthru Medicine stock?

Breakthru Medicine shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Breakthru Medicine's last funding round?

Breakthru Medicine's most recent funding round was Series A on January 29, 2026.

Who are the main investors in Breakthru Medicine?

Key investors in Breakthru Medicine include Eshelman Ventures.

Will Breakthru Medicine IPO soon?

No public IPO plans have been announced for Breakthru Medicine.

How can I track Breakthru Medicine secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Breakthru Medicine's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersPhoenix, Arizona
Employee Range13
Year Founded2024
Last FundingJan 29, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?